T2D: once-weekly semaglutide vs once-daily liraglutide

  • Capehorn MS & al.
  • Diabetes Metab
  • 10 Sep 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with uncontrolled type 2 diabetes (T2D) on 1-3 oral anti-diabetic drugs (OADs), once-weekly (OW) semaglutide 1.0 mg was superior to once-daily liraglutide 1.2 mg in improving glycaemic control and reducing body weight.

Why this matters

  • The efficacy and safety of OW semaglutide have been investigated in the SUSTAIN phase 3 clinical trial programme across the continuum of care in patients with T2D.
  • In line with findings of the LEADER trial, the SUSTAIN 6 trial showed that semaglutide significantly reduced the risk for major adverse cardiovascular (CV) events compared with placebo in patients with T2D and high CV risk.

Study design

  • SUSTAIN 10 study of 569 patients with T2D on 1-3 OADs who were randomly assigned (1:1) to receive subcutaneous OW semaglutide 1.0 mg (n=287) or once-daily liraglutide 1.2 mg (n=282).
  • Main outcomes: changes in haemoglobin A1c (HbA1c) and body weight from baseline to 30 weeks.
  • Funding: Novo Nordisk.

Key results

  • At 30 weeks, semaglutide was superior to liraglutide in reducing mean:
    • HbA1c level (estimated treatment difference [ETD], −0.69%; 95% CI, −0.82 to −0.56).
    • body weight (ETD, −3.83 kg; 95% CI, −4.57 to −3.09; P<.0001 for both>
  • A greater proportion of patients achieved HbA1c level
  • Both treatments had similar safety profiles, except for most frequent gastrointestinal disorders (43.9% vs 38.3%) and adverse events leading to premature treatment discontinuation (11.4% vs 6.6%) with semaglutide vs liraglutide.

Limitations

  • Open-label design.
  • Short-duration trial.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit